Sunshine Biopharma (SBFM) Cash from Financing Activities (2010 - 2025)

Sunshine Biopharma has reported Cash from Financing Activities for 16 years, with the latest figure at $724500.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 55.23% year-over-year to $724500.0; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (up 12.68% YoY), and the FY2025 full-year result was $4.7 million, down 46.9% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $724500.0, up from $75536.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $29.1 million in Q2 2022, with the low at -$2.1 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $3.1 million across 5 years, with a median of $724500.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 8758.42% — and 2025, when it jumped 12670.67%.
• Sunshine Biopharma's Cash from Financing Activities stood at -$23664.0 in 2021, then slumped by 8758.42% to -$2.1 million in 2022, then surged by 98.54% to -$30519.0 in 2023, then surged by 5402.28% to $1.6 million in 2024, then slumped by 55.23% to $724500.0 in 2025.
• The last three Cash from Financing Activities figures came in at $724500.0 (Q4 2025), $75536.0 (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.